Sign In
Buy IMNM
$22.76
-0.320 (-1.39%)
At Close: Jul 31, 2026
Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
07:00am, Monday, 15'th Dec 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced positive top
Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
04:00pm, Sunday, 14'th Dec 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the company wi
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 04'th Dec 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced
Intech Investment Management LLC Buys 6,141 Shares of Immunome, Inc. $IMNM
04:34am, Monday, 01'st Dec 2025
Intech Investment Management LLC increased its stake in Immunome, Inc. (NASDAQ: IMNM) by 17.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 40,5
Immunome to Present at Upcoming Investor Conferences
08:00am, Tuesday, 25'th Nov 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members o
Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update
04:05pm, Thursday, 06'th Nov 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial resu
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 04'th Nov 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced
Brighton Jones LLC Invests $98,000 in Immunome, Inc. $IMNM
03:32am, Sunday, 02'nd Nov 2025
Brighton Jones LLC acquired a new position in Immunome, Inc. (NASDAQ: IMNM) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Comm
Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference
11:51am, Friday, 31'st Oct 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome
Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance
12:00pm, Thursday, 23'rd Oct 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented preclinical
KLP Kapitalforvaltning AS Has $123,000 Holdings in Immunome, Inc. $IMNM
03:07am, Wednesday, 22'nd Oct 2025
KLP Kapitalforvaltning AS cut its stake in shares of Immunome, Inc. (NASDAQ: IMNM) by 22.8% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Comm
Immunome, Inc. (NASDAQ:IMNM) Given Average Recommendation of “Moderate Buy” by Analysts
01:32am, Wednesday, 22'nd Oct 2025
Immunome, Inc. (NASDAQ: IMNM - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eleven brokerages that are covering the company, MarketBeat Ratings reports. One equities resea
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:05pm, Thursday, 02'nd Oct 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced
Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains?
07:31am, Thursday, 25'th Sep 2025
Immunome (IMNM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Immunome stock a ‘buy' on ‘rich pipeline' of oncology therapeutics: analysts
03:00pm, Tuesday, 23'rd Sep 2025
Immunome, Inc (NASDAQ: IMNM) has a “rich pipeline of potential best and/or first-in-class targeted oncology therapeutics,” Goldman Sachs analysts wrote in a note to clients on Monday. They�
